Khalil Feras, Choi Siak Leng, Watson Estelle, Tzschentke Thomas M, Lefeber Claudia, Eerdekens Mariëlle, Freijer Jan
Grünenthal GmbH, Aachen, Germany.
J Pain Res. 2020 Nov 24;13:3107-3123. doi: 10.2147/JPR.S269549. eCollection 2020.
The main aim of this analysis was to characterize the pharmacokinetics (PK) of tapentadol in pediatric patients from birth to <18 years old who experience acute pain, requiring treatment with an opioid analgesic.
Data from four clinical trials and 148 pediatric patients who received a single dose of tapentadol oral or intravenous solution were included. Population PK analysis was performed to determine the contribution of size-related (bodyweight) and function-related (maturation) factors to the changes in oral bioavailability (F), volume of distribution (V), and clearance (CL) with age. Simulations were carried out to compare pediatric exposures to reference adult values.
A one-compartment model with allometric scaling on disposition parameters (using theoretical or estimated exponents) and maturation functions on CL and F best described tapentadol PK. The estimated allometric exponents for CL (0.603) and V (0.820) differed slightly from the theoretical values of 0.75 for CL and 1 for V. A maximum in CL/F was observed at about 2-3 years when expressed on a bodyweight basis. Results for younger children as well as the F estimate were sensitive to the scaling approach, but CL/F and V/F as a function of age for the two scaling approaches led to similar curves within the bioequivalence range except below 5 weeks of age. Model-based simulations indicated that the doses used in the included clinical trials lead to exposures within the lower half of the targeted adult exposure.
The development of tapentadol is one of the first examples following a systematic approach for analgesic drug development for children. Our analysis enabled a full characterization and robust understanding of tapentadol PK in children from birth to <18 years, including preterm infants, and showed the importance of evaluating the sensitivity of the inferences of the PK parameters to the selected scaling approach.
本分析的主要目的是描述曲马多在出生至未满18岁、经历急性疼痛且需要使用阿片类镇痛药治疗的儿科患者中的药代动力学(PK)特征。
纳入四项临床试验中148例接受单剂量曲马多口服或静脉溶液的儿科患者的数据。进行群体PK分析,以确定与大小相关(体重)和功能相关(成熟度)的因素对口服生物利用度(F)、分布容积(V)和清除率(CL)随年龄变化的影响。进行模拟以比较儿科患者与参考成人值的暴露情况。
一个处置参数采用异速缩放(使用理论或估计指数)且CL和F采用成熟度函数的一室模型最能描述曲马多的PK。CL(0.603)和V(0.820)的估计异速指数与CL为0.75、V为1的理论值略有不同。以体重为基础表示时,在约2 - 3岁时观察到CL/F的最大值。年幼儿童的结果以及F估计值对缩放方法敏感,但两种缩放方法下CL/F和V/F随年龄的变化曲线在生物等效范围内(5周龄以下除外)相似。基于模型的模拟表明,纳入的临床试验中使用的剂量导致的暴露在目标成人暴露的下半部分范围内。
曲马多的研发是儿童镇痛药系统研发方法的首批实例之一。我们的分析能够全面描述并深入理解曲马多在出生至未满18岁儿童(包括早产儿)中的PK特征,并表明评估PK参数推断对所选缩放方法的敏感性的重要性。